Cargando…
IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19
Autores principales: | Della-Torre, Emanuel, Criscuolo, Elena, Lanzillotta, Marco, Locatelli, Massimo, Clementi, Nicola, Mancini, Nicasio, Dagna, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555969/ https://www.ncbi.nlm.nih.gov/pubmed/34746843 http://dx.doi.org/10.1016/S2665-9913(21)00321-0 |
Ejemplares similares
-
Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro
por: Clementi, Nicola, et al.
Publicado: (2020) -
Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2
por: Criscuolo, Elena, et al.
Publicado: (2022) -
The right place for IL-1 inhibition in COVID-19
por: Cavalli, Giulio, et al.
Publicado: (2021) -
SARS-CoV-2 infection despite high levels of vaccine-induced anti-Receptor-Binding-Domain antibodies: a study on 1110 health-care professionals from a northern Italian university hospital
por: Ferrari, Davide, et al.
Publicado: (2022) -
JC Polyomavirus (JCV) and Monoclonal Antibodies: Friends or Potential Foes?
por: Diotti, Roberta Antonia, et al.
Publicado: (2013)